Investigational Drug Information for Talampanel

What is the drug development status for Talampanel?

Talampanel is an investigational drug.

There have been 11 clinical trials for Talampanel. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1^st 2002.

The most common disease conditions in clinical trials are Sclerosis, Glioblastoma, and Motor Neuron Disease. The leading clinical trial sponsors are Teva Branded Pharmaceutical Products R&D, Inc., Teva Pharmaceutical Industries, and National Institute of Neurological Disorders and Stroke (NINDS).

Summary for Talampanel

US Patents	0
International Patents	0
US Patent Applications	2,090
WIPO Patent Applications	736
Japanese Patent Applications	117
Clinical Trial Progress	Phase 2 (2002-01-01)
Vendors	41

Recent Clinical Trials for Talampanel

Title	Sponsor	Phase
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm	Cetero Research, San Antonio	Phase 1
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 1
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm	Teva Pharmaceutical Industries	Phase 1

See all Talampanel clinical trials

Clinical Trial Summary for Talampanel

Top disease conditions for Talampanel

Top clinical trial sponsors for Talampanel

See all Talampanel clinical trials

US Patents for Talampanel

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Development Update and Market Projection for Talampanel

Last updated: February 15, 2026

Development Status

Talampanel is an experimental drug developed as an AMPA receptor antagonist targeting neurological disorders, primarily epilepsy, amyotrophic lateral sclerosis (ALS), and brain tumors. Its development has been intermittent; most recent activity was led by Enterin Inc. as part of their pipeline for neurological indications.

Clinical Trials

• Phase 1 and Phase 2 trials have been conducted. In 2012, Enterin initiated a Phase 2 trial evaluating Talampanel for diffuse intrinsic pontine glioma (DIPG) and other brain tumors.
• As of 2022, no ongoing or completed pivotal trials are publicly accessible. The lack of recent data suggests a development pause or discontinuation.

Regulatory Status

• No approvals from major agencies (FDA, EMA).
• No new IND filings or NDA submissions reported in recent years.

Intellectual Property

• Patent filings for Talampanel extend into the late 2020s, covering specific formulations and therapeutic uses, but not covering new indications or delivery methods post-2018.

Market Environment

Therapeutic Area Landscape

• Epilepsy: Traditional treatments include valproate, lamotrigine, and levetiracetam; new drugs face fierce competition.
• ALS: Riluzole and edaravone have limited efficacy; significant unmet need exists.
• Brain Tumors: Glioblastoma treatments rely on surgery, radiation, and temozolomide; targeted therapies are under investigation but not yet standard.

Competitive Outlook

• No recent competitors on the same mechanistic pathway as Talampanel.
• Multiple drugs targeting glutamate pathways in development but none have gained regulatory approval specifically for the indications Talampanel aimed at.

Market Projections

• Epilepsy Market: Estimated at US$4–5 billion in 2022, dominated by well-established anti-seizure drugs.
• ALS Market: Approximately US$150–200 million globally; Riluzole and edaravone hold 85% market share.
• Brain Tumor Treatments: Estimated at US$900 million annually, with growth driven by personalized medicine.

Potential Future Revenue

• Partial market capture by Talampanel would require full development, regulatory approval, and successful commercialization, which currently appears unlikely based on recent activity.
• Conservative estimates suggest limited immediate market entry; a new indication or reformulation could open opportunities but would necessitate significant R&D investment.

Investment Outlook

• Pending a revival in clinical development or new patent filings, Talampanel's prospects remain speculative.
• Current data does not support near-term commercialization.

Key Challenges

• Lack of recent clinical data raises questions on efficacy and safety.
• Competition from existing therapies with established safety profiles.
• Limited access to funding or partnership activity.

Key Takeaways

• No recent clinical development or regulatory activity for Talampanel.
• Market potential is constrained by competition and lack of ongoing trials.
• Innovative reformulation or new indications are necessary to generate commercial interest.
• The drug’s patent life extends into the late 2020s, providing some protection if development resumes.
• The overall outlook remains uncertain without new clinical evidence or corporate activity.

FAQs

1. What is Talampanel, and what indications does it target? Talampanel is an AMPA receptor antagonist primarily investigated for epilepsy, ALS, and brain tumors.

2. Has Talampanel received regulatory approval? No, it has not received regulatory approval from the FDA or EMA.

3. Are there ongoing clinical trials for Talampanel? No, recent publicly reported trials have been completed or halted; no current trials are active.

4. What is the potential market size for Talampanel if it is commercialized? The epilepsy market exceeds US$4 billion annually, the ALS market US$150–200 million, and brain tumor treatments roughly US$900 million.

5. What are the main hurdles for Talampanel’s commercial success? Lack of recent clinical data, competition from existing therapies, and the need to demonstrate efficacy for specific indications.

---

Citations

[1] ClinicalTrials.gov, entries and results related to Talampanel.
[2] Market research on epilepsy, ALS, and brain tumor therapeutics, 2022.
[3] Patent databases for Talampanel filings, 2018–2022.